186 related articles for article (PubMed ID: 35177777)
21. The role of heterocellular hereditary persistence of fetal haemoglobin in beta(0)-thalassaemia intermedia.
Chang YP; Littera R; Garau R; Smith KD; Dover GJ; Iannelli S; Cacace E; Contu L
Br J Haematol; 2001 Sep; 114(4):899-906. PubMed ID: 11564083
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia.
Haghpanah S; Zarei T; Eshghi P; Zekavat O; Bordbar M; Hoormand M; Karimi M
Ann Hematol; 2018 Oct; 97(10):1919-1924. PubMed ID: 29926158
[TBL] [Abstract][Full Text] [Related]
23. Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients.
Yavarian M; Karimi M; Bakker E; Harteveld CL; Giordano PC
Haematologica; 2004 Oct; 89(10):1172-8. PubMed ID: 15477200
[TBL] [Abstract][Full Text] [Related]
24. Response to hydroxyurea therapy in beta-thalassemia.
Koren A; Levin C; Dgany O; Kransnov T; Elhasid R; Zalman L; Palmor H; Tamary H
Am J Hematol; 2008 May; 83(5):366-70. PubMed ID: 18181203
[TBL] [Abstract][Full Text] [Related]
25. Hydroxyurea in the treatment of major beta-thalassemia and importance of genetic screening.
Alebouyeh M; Moussavi F; Haddad-Deylami H; Vossough P
Ann Hematol; 2004 Jul; 83(7):430-3. PubMed ID: 14722738
[TBL] [Abstract][Full Text] [Related]
26. Hydroxyurea therapy in beta-thalassaemia intermedia: improvement in haematological parameters due to enhanced beta-globin synthesis.
Zeng YT; Huang SZ; Ren ZR; Lu ZH; Zeng FY; Schechter AN; Rodgers GP
Br J Haematol; 1995 Jul; 90(3):557-63. PubMed ID: 7646994
[TBL] [Abstract][Full Text] [Related]
27. Comparison of MicroRNAs Mediated in Reactivation of the γ-Globin in β-Thalassemia Patients, Responders and Non-Responders to Hydroxyurea.
Hojjati MT; Azarkeivan A; Pourfathollah AA; Amirizadeh N
Hemoglobin; 2017 Mar; 41(2):110-115. PubMed ID: 28696844
[TBL] [Abstract][Full Text] [Related]
28. Long-term hydroxyurea therapy in beta-thalassaemia patients.
de Paula EV; Lima CS; Arruda VR; Alberto FL; Saad ST; Costa FF
Eur J Haematol; 2003 Mar; 70(3):151-5. PubMed ID: 12605659
[TBL] [Abstract][Full Text] [Related]
29. Response to hydroxyurea in beta thalassemia major and intermedia: experience in western India.
Italia KY; Jijina FJ; Merchant R; Panjwani S; Nadkarni AH; Sawant PM; Nair SB; Ghosh K; Colah RB
Clin Chim Acta; 2009 Sep; 407(1-2):10-5. PubMed ID: 19545554
[TBL] [Abstract][Full Text] [Related]
30. Hydroxyurea in sickle cell disease--a study of clinico-pharmacological efficacy in the Indian haplotype.
Italia K; Jain D; Gattani S; Jijina F; Nadkarni A; Sawant P; Nair S; Mohanty D; Ghosh K; Colah R
Blood Cells Mol Dis; 2009; 42(1):25-31. PubMed ID: 18954999
[TBL] [Abstract][Full Text] [Related]
31. Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial.
Howard J; Ataga KI; Brown RC; Achebe M; Nduba V; El-Beshlawy A; Hassab H; Agodoa I; Tonda M; Gray S; Lehrer-Graiwer J; Vichinsky E
Lancet Haematol; 2021 May; 8(5):e323-e333. PubMed ID: 33838113
[TBL] [Abstract][Full Text] [Related]
32. Hydroxyurea increases hemoglobin F levels and improves the effectiveness of erythropoiesis in beta-thalassemia/hemoglobin E disease.
Fucharoen S; Siritanaratkul N; Winichagoon P; Chowthaworn J; Siriboon W; Muangsup W; Chaicharoen S; Poolsup N; Chindavijak B; Pootrakul P; Piankijagum A; Schechter AN; Rodgers GP
Blood; 1996 Feb; 87(3):887-92. PubMed ID: 8562958
[TBL] [Abstract][Full Text] [Related]
33. Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran.
Karimi M; Haghpanah S; Farhadi A; Yavarian M
Int J Hematol; 2012 Jan; 95(1):51-6. PubMed ID: 22180324
[TBL] [Abstract][Full Text] [Related]
34. Single and combination drug therapy for fetal hemoglobin augmentation in hemoglobin E-beta 0-thalassemia: Considerations for treatment.
Singer ST; Kuypers FA; Olivieri NF; Weatherall DJ; Mignacca R; Coates TD; Davies S; Sweeters N; Vichinsky EP
Ann N Y Acad Sci; 2005; 1054():250-6. PubMed ID: 16339672
[TBL] [Abstract][Full Text] [Related]
35. Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia.
Bradai M; Pissard S; Abad MT; Dechartres A; Ribeil JA; Landais P; de Montalembert M
Transfusion; 2007 Oct; 47(10):1830-6. PubMed ID: 17880608
[TBL] [Abstract][Full Text] [Related]
36. Clinical and laboratory effects of long-term administration of hydroxyurea to patients with sickle-cell/beta-thalassaemia.
Voskaridou E; Kalotychou V; Loukopoulos D
Br J Haematol; 1995 Mar; 89(3):479-84. PubMed ID: 7537527
[TBL] [Abstract][Full Text] [Related]
37. A phase 2 study of HQK-1001, an oral fetal haemoglobin inducer, in β-thalassaemia intermedia.
Inati A; Kahale M; Perrine SP; Chui DH; Taher AT; Koussa S; Abi Nasr T; Abbas HA; Ghalie RG
Br J Haematol; 2014 Feb; 164(3):456-8. PubMed ID: 24224649
[No Abstract] [Full Text] [Related]
38. Role of Genomic Biomarkers in Increasing Fetal Hemoglobin Levels Upon Hydroxyurea Therapy and in β-Thalassemia Intermedia: A Validation Cohort Study.
Kolliopoulou A; Siamoglou S; John A; Sgourou A; Kourakli A; Symeonidis A; Vlachaki E; Chalkia P; Theodoridou S; Ali BR; Katsila T; Patrinos GP; Papachatzopoulou A
Hemoglobin; 2019 Jan; 43(1):27-33. PubMed ID: 31039620
[TBL] [Abstract][Full Text] [Related]
39. Hydroxyurea in thalassemia intermedia--a promising therapy.
Dixit A; Chatterjee TC; Mishra P; Choudhry DR; Mahapatra M; Tyagi S; Kabra M; Saxena R; Choudhry VP
Ann Hematol; 2005 Jul; 84(7):441-6. PubMed ID: 15838670
[TBL] [Abstract][Full Text] [Related]
40. Advances in experimental treatment of beta-thalassaemia.
Rodgers GP; Saunthararajah Y
Expert Opin Investig Drugs; 2001 May; 10(5):925-34. PubMed ID: 11322866
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
